KDR and gastric cancer: However, most patients with advanced GC might be refractory to first-line treatment, and the second-line therapeutic options included docetaxel, paclitaxel, irinotecan monotherapy, or the antivascular endothelial growth factor receptor (VEGFR2) antibody ramucirumab alone or in combination with paclitaxel [9].